Insights from 2023 ASH Annual Meeting
Playback speed
10 seconds
ASH 2023 Insights: "A Comparison of HMAs Combined With Ivosidenib or Venetoclax in Newly Diagnosed Patients With IDH1mut AML - A RWE Study"
By
Insights from 2023 ASH Annual Meeting
FEATURING
Alexander Ambinder
By
Insights from 2023 ASH Annual Meeting
FEATURING
Alexander Ambinder
37 views
December 19, 2023
Login to view comments.
Click here to Login
Leukemia